Characteristics of patients with AML who received IC after HMA and VEN
| . | All (N=46) . |
|---|---|
| Sex, n (%) | |
| Female | 20 (43) |
| Male | 26 (57) |
| Age, median (interquartile range), y | 65 (50-68) |
| Diagnosis, n (%) | |
| AML | 37 (80) |
| MDS/AML | 9 (20) |
| AML classification, n (%) | |
| Recurrent genetic abnormality | 13 (28) |
| TP53 (mutated or lost) | 8 (17) |
| Myelodysplasia-related gene mutation | 14 (30) |
| Myelodysplasia-related cytogenetic abnormality | 5 (11) |
| Not otherwise specified | 6 (13) |
| AML qualifier, n (%) | |
| Therapy-related | 7 (15) |
| Prior MDS or MDS/MPN | 19 (41) |
| Germ line predisposition | 1 (2) |
| None | 19 (41) |
| ELN 2022 risk classification, n (%) | |
| Favorable | 4 (9) |
| Intermediate | 10 (22) |
| Adverse | 31 (67) |
| Unknown | 1 (2) |
| VEN combination, n (%) | |
| AZA | 37 (80) |
| Decitabine | 9 (20) |
| HMA/VEN line of treatment, n (%) | |
| 1L | 24 (52) |
| 2L+ | 22 (48) |
| Prior HMA, n (%) | 9 (20) |
| Prior IC, n (%) | 21 (46) |
| Prior transplant, n (%) | 15 (33) |
| HMA/VEN cycles, median (interquartile range) | 2 (2-4) |
| HMA/VEN response, n (%) | |
| CR | 6 (13) |
| CRi | 5 (11) |
| MLFS | 3 (7) |
| PR | 1 (2) |
| NR | 31 (67) |
| . | All (N=46) . |
|---|---|
| Sex, n (%) | |
| Female | 20 (43) |
| Male | 26 (57) |
| Age, median (interquartile range), y | 65 (50-68) |
| Diagnosis, n (%) | |
| AML | 37 (80) |
| MDS/AML | 9 (20) |
| AML classification, n (%) | |
| Recurrent genetic abnormality | 13 (28) |
| TP53 (mutated or lost) | 8 (17) |
| Myelodysplasia-related gene mutation | 14 (30) |
| Myelodysplasia-related cytogenetic abnormality | 5 (11) |
| Not otherwise specified | 6 (13) |
| AML qualifier, n (%) | |
| Therapy-related | 7 (15) |
| Prior MDS or MDS/MPN | 19 (41) |
| Germ line predisposition | 1 (2) |
| None | 19 (41) |
| ELN 2022 risk classification, n (%) | |
| Favorable | 4 (9) |
| Intermediate | 10 (22) |
| Adverse | 31 (67) |
| Unknown | 1 (2) |
| VEN combination, n (%) | |
| AZA | 37 (80) |
| Decitabine | 9 (20) |
| HMA/VEN line of treatment, n (%) | |
| 1L | 24 (52) |
| 2L+ | 22 (48) |
| Prior HMA, n (%) | 9 (20) |
| Prior IC, n (%) | 21 (46) |
| Prior transplant, n (%) | 15 (33) |
| HMA/VEN cycles, median (interquartile range) | 2 (2-4) |
| HMA/VEN response, n (%) | |
| CR | 6 (13) |
| CRi | 5 (11) |
| MLFS | 3 (7) |
| PR | 1 (2) |
| NR | 31 (67) |
PR, partial remission; NR, no response.